Personalis, Inc. Appoints Industry Veteran Stephen Moore as General Counsel
06 5월 2020 - 3:00AM
Business Wire
Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics
for cancer, today announced the appointment Stephen Moore as
General Counsel.
“We are very pleased to welcome Stephen to the Personalis team.
He has an impressive track record with more than 20 years of
in-house legal experience at advanced genomics companies,” said
John West, President and Chief Executive Officer of Personalis.
“This expertise will provide critical support as we advance
Personalis.”
Mr. Moore joins Personalis after a decade at Pacific Biosciences
(NASDAQ: PACB), where he served as General Counsel. Prior to
Pacific Biosciences, Mr. Moore was General Counsel at Navigenics, a
consumer genomics company that was later acquired by Life
Technologies (now part of Thermo Fisher Scientific). Prior to
Navigenics, he worked for over eight years at DNA microarray
pioneer Affymetrix (which was also later acquired by Thermo Fisher
Scientific), where he was most recently an Associate General
Counsel. Mr. Moore holds a Bachelor of Arts degree in Political
Science from San Jose State University, and a law degree from the
University of California, Davis.
“I am pleased to join the Personalis team at this important time
for the company,” said Mr. Moore. “After many years working at
leading genomics tool and service providers with a shared vision
that providing increasingly more comprehensive genomic information
is critical to advancing our understanding of biological processes,
I am enthusiastic to take part in the large-scale application of
that vision to human health as Personalis grows its commercial
operations and seeks to expand its market presence in
immuno-oncology and potentially other disease areas, and in
population-sized genome sequencing projects such as the VA
MVP.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company
transforming the development of next-generation therapies by
providing more comprehensive molecular data about each patient’s
cancer and immune response. The Personalis ImmunoID NeXT Platform™
is designed to adapt to the complex and evolving understanding of
cancer, providing its biopharmaceutical customers with information
on all of the approximately 20,000 human genes, together with the
immune system, from a single tissue sample. Personalis also
provides genomic information to the VA Million Veterans Program as
part of their goal to sequence over a million veteran genomes. The
Personalis Clinical Laboratory is GxP-aligned as well as
CLIA’88-certified and CAP-accredited. For more information, please
visit www.personalis.com and follow Personalis on Twitter
(@PersonalisInc).
Forward-Looking Statements
This press release contains or may imply "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934. For
example, forward-looking statements include statements regarding
the potential advancement of or growth opportunities for
Personalis’ business, expansion of Personalis’ market presence in
immuno-oncology, the company’ services for the VA Million Veterans
Program or other large-scale population sequencing projects, and
other future events. These forward-looking statements are subject
to risks and uncertainties, including those related to the
evolution of cancer therapies and market adoption of our services,
our expectations regarding future performance, and the COVID-19
pandemic, as well as other risks and uncertainties discussed in
Personalis’ filings with the Securities and Exchange Commission
(SEC), including in the “Risk Factors” and “Management’s Discussion
and Analysis of Financial Condition and Results of Operations”
sections of the Company’s most recently filed periodic reports on
Forms 10-K and 10-Q and subsequent filings and in the documents
incorporated by reference therein, all of which may significantly
impact our business and operations, the business and operations of
our customers, our ability to access capital and the value of our
common stock. Except as otherwise required by law, Personalis
disclaims any intention or obligation to update or revise any
forward-looking statements, which speak only as of the date hereof,
whether as a result of new information, future events or
circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200505005867/en/
Investor Relations Contact for Personalis: Caroline
Corner investors@personalis.com 415-202-5678
Media Contact for Personalis: Jennifer Havlek
pr@personalis.com www.personalis.com 650-752-1300
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Personalis (NASDAQ:PSNL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024